ESTRO 2024 - Abstract Book

S945

Clinical - CNS

ESTRO 2024

Stereotactic radiosurgery is a well-established, efficient and safety option for the treatment of TN, associated with a low risk of facial side effects. Is possible to obtain pain relief from a multirefractory TN using this treatment.

Keywords: Trygeminal neuralgia, radiosurgery, exactrac

2737

Digital Poster

Development of a fast neurocognitive evaluation tool in GBM patients undergoing radiotherapy

Aida Angela Tummolo 1 , Serena Bracci 2 , Beatrice Di Capua 3 , Ciro Mazzarella 2 , Francesco Beghella Bartoli 2 , Antonella Martino 2 , Roberta Bertolini 2 , Silvia Mariani 2 , Loredana Dinapoli 2,4 , Andrea Bellieni 2 , Vincenzo Valentini 2 , Silvia Chiesa 2 , Giuseppe Ferdinando Colloca 2 , Luca Tagliaferri 2 , Maria Antonietta Gambacorta 2 1 Università Cattolica del Sacro Cuore, Radioterapia Oncologica ed Ematologia, Roma, Italy. 2 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Radioterapia Oncologica ed Ematologia, Roma, Italy. 3 Centro di Eccellenza Oncologia Radioterapica e Medica e Radiologia, Fatebenefratelli Isola Tiberina Gemelli Isola, Roma, Italy. 4 Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Psicologia Clinica, Roma, Italy

Purpose/Objective:

Neurocognitive function assessment is essential in glioblastoma (GBM) patients. However, several tools are available, and in clinical practice, physicians need a quick and practical assessment. We hypothesized to use a clock drawing test (CDT) as a rapid screening tool and to evaluate its sensitivity level and we compared it with the mini mental state examination (MMSE). The primary outcome is to evaluate whether the CDT can be superimposed on other tests already used in literature to assess cognitive framework of patients affected by GBM. The secondary outcome is to evaluate if neurocognitive assessment correlates with overall survival, compliance and progression free survival.

Material/Methods:

We considered patients with a new diagnosis of GBM IDH wild type, undergoing adjuvant radiation-chemotherapy within 7 days from the neuropsychological evaluation. We administered the clock drawing test (CDT)(Fig1)and a questionnaire on the percieved neurocognitive function (FACT-Cog survey).The assessment timing is before adjuvant treatment starts, at the end of treatment and three months after the end of radiochemotherapy.

Results:

The study started in May 2023 and currently nine patients with GBM were enrolled (median age: 61 years). We first used the CDT and then administered the MMSE to validate the CDT result, taking about 10 minutes. In only 1/9 cases, the CDT result was not correlated with MMSE (CDT 1/3; MMSE 26.2/30), while in 8/9 cases we found an agreement between the CDT and MMSE results. From the analysis of the FACT-Cog survey, we also observed an